Long Non-Coding RNA Myosin Light Chain Kinase Antisense 1 Plays an Oncogenic Role in Gallbladder Carcinoma by Promoting Chemoresistance and Proliferation

References

• LeeSH, KimJM, LeeDG, et al. Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation. Cell Death Differ. 2020;28(3):968–984.32989241
   PubMed Web of Science ®Google Scholar
• XuS, ZhanM, JiangC, et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat Commun. 2019;10:5492. doi:10.1038/s41467-019-13420-x31792210
   PubMed Web of Science ®Google Scholar
• MaL, BajicVB, ZhangZ. On the classification of long non-coding RNAs. RNA Biol. 2013;10:925–933. doi:10.4161/rna.2460423696037
   PubMed Web of Science ®Google Scholar
• AnastasiadouE, JacobLS, SlackFJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18:5–18. doi:10.1038/nrc.2017.9929170536
   PubMed Web of Science ®Google Scholar
• ZhangPF, WuJ, WuY, et al. The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA-342-3p target sequence. J Cell Physiol. 2019;234:10157–10165. doi:10.1002/jcp.2768430443961
   PubMed Web of Science ®Google Scholar
• LuoJ, XiangH. LncRNA MYLK-AS1 acts as an oncogene by epigenetically silencing large tumor suppressor 2 (LATS2) in gastric cancer. Bioengineered. 2021;12:3101–3112. doi:10.1080/21655979.2021.194401934181498
   PubMed Web of Science ®Google Scholar
• TengF, ZhangJX, ChangQM, et al. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39:235. doi:10.1186/s13046-020-01739-z33168027
   PubMed Web of Science ®Google Scholar
• ZhuS, ZhangJ, GaoX, et al. Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2. J Cell Physiol. 2021;236:5757–5770. doi:10.1002/jcp.3025933438217
   PubMed Web of Science ®Google Scholar
• JinL, CaiQ, WangS, et al. Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer. Cell Death Dis. 2018;9:1017. doi:10.1038/s41419-018-1064-130282996
   PubMed Web of Science ®Google Scholar
• WangSH, YangY, WuXC, et al. Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression. Cancer Lett. 2016;380:122–133. doi:10.1016/j.canlet.2016.06.01927345740
   PubMed Web of Science ®Google Scholar
• WuY, HuL, LiangY, et al. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Mol Cancer. 2017;16:150. doi:10.1186/s12943-017-0715-728854977
   PubMed Web of Science ®Google Scholar
• YiewNKH, GreenwayC, ZarzourA, et al. Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: role of apolipoprotein E. J Biol Chem. 2019;294:8577–8591. doi:10.1074/jbc.RA118.00687130971429
   PubMed Web of Science ®Google Scholar
• JonesBA, VaramballyS, ArendRC. Histone methyltransferase EZH2: a therapeutic target for ovarian cancer. Mol Cancer Ther. 2018;17:591–602. doi:10.1158/1535-7163.MCT-17-043729726819
   PubMed Web of Science ®Google Scholar
• ZhangPF, GaoC, HuangXY, et al. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer. 2020;19:110. doi:10.1186/s12943-020-01222-532593303
   PubMed Web of Science ®Google Scholar
• JiaB, XieT, QiuX, et al. Long noncoding RNA FALEC inhibits proliferation and metastasis of tongue squamous cell carcinoma by epigenetically silencing ECM1 through EZH2. Aging (Albany NY). 2019;11:4990.31335317
   PubMedGoogle Scholar
• ZhaoY, DingL, WangD, et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019;38:e99599. doi:10.15252/embj.20189959930723117
   PubMed Web of Science ®Google Scholar
• RamakrishnanS, GrangerV, RakM, et al. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death Differ. 2019;26:2100–2114. doi:10.1038/s41418-019-0278-930692641
   PubMed Web of Science ®Google Scholar
• XuM, ChenX, LinK, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J Hematol Oncol. 2019;12:3. doi:10.1186/s13045-018-0690-530626446
   PubMed Web of Science ®Google Scholar
• JinL, CaiQ, WangS, WangS, WangJ, QuanZ. Long noncoding RNA PVT1 promoted gallbladder cancer proliferation by epigenetically suppressing miR-18b-5p via DNA methylation. Cell Death Dis. 2020;11:871. doi:10.1038/s41419-020-03080-x33067424
   PubMed Web of Science ®Google Scholar
• YangG, WangJ, HuangB. Loss of miR-217 promotes osteosarcoma cell proliferation through targeting SETD8. Pharmazie. 2018;73:711–714.30522554
   PubMed Web of Science ®Google Scholar
• GaoY, WangB, LuoH, ZhangQ, XuM. miR-217 represses TGF-beta1-induced airway smooth muscle cell proliferation and migration through targeting ZEB1. Biomed Pharmacother. 2018;108:27–35. doi:10.1016/j.biopha.2018.09.03030212709
   PubMed Web of Science ®Google Scholar
• PanB, YangJ, WangX, XuK, IkezoeT. miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. Exp Hematol. 2018;68:80–88e2. doi:10.1016/j.exphem.2018.09.00130195077
   PubMed Web of Science ®Google Scholar
• YanJ, WuG, ChenJ, XiongL, ChenG, LiP. Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia. Cancer Biomark. 2018;22:73–78. doi:10.3233/CBM-17093629439315
   PubMed Web of Science ®Google Scholar
• FlumM, KleemannM, SchneiderH, et al. miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells. J Cell Commun Signal. 2018;12:451–466. doi:10.1007/s12079-017-0410-x28905214
   PubMed Web of Science ®Google Scholar
• DongJ, WangM, NiD, et al. MicroRNA-217 functions as a tumor suppressor in cervical cancer cells through targeting Rho-associated protein kinase 1. Oncol Lett. 2018;16:5535–5542.30344707
   PubMed Web of Science ®Google Scholar
• HeckmannD, MaierP, LaufsS, et al. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1alpha-induced gene expression, invasion and chemosensitivity of colon cancer. Clin Cancer Res. 2014;20:604–616. doi:10.1158/1078-0432.CCR-13-058224255072
   PubMed Web of Science ®Google Scholar
• WangH, QinR, GuanA, et al. HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. J Cell Biochem. 2018;119:7226–7234. doi:10.1002/jcb.2690129856087
   PubMed Web of Science ®Google Scholar
• GuoJ, FengZ, HuangZ, WangH, LuW. MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol Cells. 2014;37:664–671. doi:10.14348/molcells.2014.012125234467
   PubMed Web of Science ®Google Scholar
• MargueronR, ReinbergD. The polycomb complex PRC2 and its mark in life. Nature. 2011;469:343–349. doi:10.1038/nature0978421248841
   PubMed Web of Science ®Google Scholar
• QiuX, WangW, LiB, et al. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells. BMC Cancer. 2019;19:27. doi:10.1186/s12885-018-5228-230621625
   PubMed Web of Science ®Google Scholar
• WuY, ZhangZ, CenciariniME, et al. Tamoxifen resistance in breast cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional axis. Cancer Res. 2018;78:671–684. doi:10.1158/0008-5472.CAN-17-132729212856
   PubMed Web of Science ®Google Scholar